Treatment of fungal infections of the central nervous system

Annals of Neurology

Volumn 9, Issue 5, 1981, Pages 417-422

  Bell, William E ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCYTOSINE; KETOCONAZOLE; MICONAZOLE;

BRAIN ABSCESS; BRAIN GRANULOMA; CENTRAL NERVOUS SYSTEM; DRUG THERAPY; FUNGUS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MENINGITIS; MENINGOENCEPHALITIS; MYCOSIS; OCCLUSIVE CEREBROVASCULAR DISEASE; REVIEW; THERAPY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CHEMISTRY; FLUCYTOSINE; HUMAN; KIDNEY DISEASES; MICONAZOLE; MYCOSES;

EID: 0019482494     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410090502     Document Type: Article

References (48)

1. Use of a hyperbaric solution for administration of intrathecal amphotericin B
2. Amphotericin B pharmacokinetics in humans
3. Pharmacokinetics of intrathecally administered amphotericin B
4. Unusual serum lipoprotein abnormality induced by the vehicle of miconazole
5. Systemic nocardiosis treated with trimethoprim and sulphamethoxazole
6. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis
7. Cryptococcal meningitis. Fatal marrow aplasia from combined therapy
8. Pharmacology, toxicity, and therapeutic usefulness of amphotericin B
9. Amphotericin B therapy in children. A review of the literature and a case report
10. Excretion pathways of amphotericin B
11. Use of 5‐fluorocytosine in patients with impaired renal function
12. Treatment of fungal meningitis with miconazole
13. Coccidioidomycosis in compromised hosts. Experience at Stanford University Hospital
14. A subcutaneous reservoir for intrathecal therapy of fungal meningitis
15. Evidence for conversion of 5‐fluorocytosine to 5‐fluorouracil in humans: possible factor in 5‐fluorocytosine clinical toxicity
16. Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R 41,000
17. Coccidioidomycosis. Part I
18. Coccidioidomycosis. Part II
19. Treatment of disseminated mycotic infections. A new approach to amphotericin B therapy
20. 5‐Flurocytosine in the treatment of cryptococcal and candida mycoses
21. Treatment of mucocutaneous candidiasis with transfer factor
22. Complications with the Ommaya reservoir in patients with graulomatous meningitis
23. Disseminated cryptococcus treated with transfer factor
24. Mycotic infections in leukemic patients at autopsy
25. Treatment of fungal infections with flucytosine
26. Comparative susceptibility of four kinds of pathogenic fungi to amphotericin B and amphotericin B methyl ester
27. Nephrotoxicity of amphotericin B. A clinical‐pathologic study
28. Distribution of radiolabelled amphotericin B Methyl ester and amphotericin B in non‐human primates
29. Miconazole therapy for treatment of fungal infections in cancer patients
30. Bone marrow toxicity associated with 5‐flurocytosine therapy
31. Erythropoietin concentration in amphotericin B‐induced anemia
32. Strategies in the treatment of systemic fungal infections
33. Fatal aplastic anemia resulting from flucytosine
34. Synergism of amphotericin B and 5‐fluorocytosine fo. Candida species
35. Diagnostic and therapeutic considerations in Nocardia asteroides infection
36. The emergence of candidosis. The dominant postmortem cerebral mycosis
37. Systemic fungal infections complicating renal transplantation and immunosuppressive therapy
38. Neuropathology of cardiac transplantation. Survey of 31 cases
39. Bacteremia and fungemia complicating neoplicating neoplastic disease. A study of 364 cases
40. Therapy for disseminated coccidioidomycosis with transfer factor from a related donor
41. Miconazole in coccidioidomycosis. II. Therapeutic and pharmacologic studies in man
42. Miconazole therapy for fungal meningitis
43. Amphotericin B toxicity
44. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B
45. Biochemical effects of miconazole on fungi. I. Effects on the uptake and/or utilization of purines, pyrimidines, nucleosides, amino acids and glucose by Candida albicans
46. 5‐Fluorocytosine in the treatment of mycotic infections
47. Toxicity of amphotericin B in children with cancer